Abstract
LRRK2 is currently considered to be a potential therapeutic target for the treatment of Parkinson’s disease. A number of pathological mutations, the majority of which lie in the dual catalytic domains of LRRK2, segregate with Parkinson’s disease in an autosomal-dominant fashion. The most common mutation, G2019S, results in an increase in the kinase activity of LRRK2 and much work has, therefore, gone into the development of potent and specific inhibitors of LRRK2 kinase activity. A number of LRRK2 kinase inhibitors have now been employed in the search for the physiological function of LRRK2 and the targets of LRRK2 kinase activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
